Invesco Ltd. lessened its position in Cassava Sciences, Inc. (NASDAQ:SAVA - Free Report) by 95.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 15,408 shares of the company's stock after selling 290,882 shares during the period. Invesco Ltd.'s holdings in Cassava Sciences were worth $36,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Sequoia Financial Advisors LLC bought a new position in Cassava Sciences in the 4th quarter valued at approximately $26,000. Johnson Investment Counsel Inc. boosted its position in shares of Cassava Sciences by 71.4% during the fourth quarter. Johnson Investment Counsel Inc. now owns 12,000 shares of the company's stock valued at $28,000 after buying an additional 5,000 shares during the last quarter. Catalina Capital Group LLC bought a new stake in Cassava Sciences in the 4th quarter worth about $32,000. Intech Investment Management LLC increased its holdings in Cassava Sciences by 64.8% in the 4th quarter. Intech Investment Management LLC now owns 20,898 shares of the company's stock worth $49,000 after buying an additional 8,220 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Cassava Sciences during the 4th quarter valued at about $51,000. Hedge funds and other institutional investors own 38.05% of the company's stock.
Analyst Ratings Changes
Separately, HC Wainwright reissued a "neutral" rating and set a $2.00 price objective on shares of Cassava Sciences in a report on Tuesday, March 25th.
Read Our Latest Analysis on SAVA
Cassava Sciences Price Performance
Shares of SAVA traded up $0.07 during trading hours on Friday, hitting $1.77. The stock had a trading volume of 1,154,539 shares, compared to its average volume of 2,956,140. Cassava Sciences, Inc. has a 12 month low of $1.15 and a 12 month high of $42.20. The stock has a fifty day moving average price of $1.86 and a 200 day moving average price of $6.39. The firm has a market capitalization of $85.51 million, a PE ratio of -1.28 and a beta of -2.31.
Cassava Sciences (NASDAQ:SAVA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.48) earnings per share for the quarter. As a group, analysts anticipate that Cassava Sciences, Inc. will post -3.97 EPS for the current fiscal year.
Cassava Sciences Profile
(
Free Report)
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Further Reading
Before you consider Cassava Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cassava Sciences wasn't on the list.
While Cassava Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
